Context Therapeutics, Inc.

PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in the following investor conferences in November: Guggenheim Global Healthcare Conference: Fireside chat on Monday, November 11, 2024, at 3:00 p.m. ET in Boston, MA. UBS Global Healthcare Conference: Fireside chat on Wednesday, November 13, 2024, at 11:45 a.m. PT in Rancho Palos Verdes, CA. Stifel 2024 Healthcare Conference: Presentation on Tuesday, November 19, 2024 at 1:50 p.m. ET in New York, NY. Context will also participate in one-on-one meetings at each of the above conferences. A live webcast of each presentation will be available on the News and Events section of the Company’s website at https://ir.contexttherapeutics.com. Replays will be available on the website for 90 days. About Context Therapeutics®Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn. Forward-looking StatementsThis press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company and its employees to participate in and present at conferences, (ii) the potential benefits, characteristics, safety and side effect profile of our product candidates, and (iii) the likelihood data will support future development. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise. Investor Relations Contact:Jennifer Minai-AzaryChief Financial OfficerContext Therapeutics Inc.IR@contexttherapeutics.com

PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company’s clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: Title:Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6Authors:Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, Eric ButzAbstract Number:1288Date and Time:Saturday, November 9, 2024, 9:00a.m. CDTLocation:Exhibit Halls AB For more information and to view the abstract, visit the SITC 39th Annual Meeting website. About CTIM-76CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric, and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy. About Context Therapeutics®Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn. Forward-looking StatementsThis press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company, its employees and certain SITC presenters to participate in and present at conferences, (ii) the potential benefits, characteristics, safety and side effect profile of our product candidates, and (iii) the likelihood data will support future development. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise. Investor Relations Contact:Jennifer Minai-AzaryChief Financial OfficerContext Therapeutics Inc.IR@contexttherapeutics.com

本周，生物医药授权合作领域持续活跃。Insight 数据库显示，本周全球范围内共发生 24 项医药交易（截至 9 月 27 日），涉及赛诺菲、诺华、默沙东、君实生物、信念医药、瑞博生物等多家公司。 其中： 诺华与 Generate 公司进行多靶点合作，以发现和开发跨越多个疾病领域的蛋白疗法，该项合作总金额超过 10 亿美元； 赛诺菲先后达成两次合作，不仅 2700 万美元战略投资 Ventyx 公司，获得后者 CNS 渗透剂的独家首次谈判权，而且斥资约 17 亿元牵手天境生物，获得后者 CD73 抗体莱利单抗在大中华区权利； 君实生物子公司君拓生物引进一款小核酸免疫调节剂，该项合作总金额达 15.8 亿元； 另外，还有多家海外公司就技术平台或产品达成合作，涉及 ADC、基因治疗、双抗、人工智能（AI）、肝外递送等方向。 下面，Insight 数据库将分别节选部分备受关注的交易案例做介绍，仅供读者参阅。 诺华、赛诺菲、默沙东等跨国药企达成新合作   诺华超 10 亿美元布局 AI 制药 Generate 公司宣布与诺华进行多靶点合作，以发现和开发跨越多个疾病领域的蛋白疗法。根据协议，Generate 公司将获得 6500 万美元的预付款，并有资格获得超过 10 亿美元的里程碑付款，此外还有高达两位数的分级特许权使用费。 该合作将利用 Generate 公司专有的生成 AI 平台，通过基于 AI 的优化和从头生成来创建潜在 First-in-class 和 Best-in-class 分子。此次合作将结合诺华在目标生物学、生物制剂开发和临床开发方面的专业知识与能力，以创造新的治疗方法并加快药物发现和开发步伐。   赛诺菲约 17 亿元获天境生物 CD73 抗体权益 赛诺菲与天境生物达成合作，获得后者 CD73 抗体尤莱利单抗在大中华区的开发、生产和商业化权利。为此，赛诺菲将支付约 3200 万欧元的首付款和近期里程碑付款，以及特定的注册和销售里程碑付款。该合作潜在总对价最高不超过 2.13 亿欧元（约合 17 亿人民币）。 尤莱利单抗是一款差异化的 CD73 抗体，通过结合独特的 C 端表位，以单分子单价结合 CD73 内二聚体的作用方式有效抑制 CD73 活性，联合免疫检查点类药物有望提升肿瘤治疗协同疗效。该产品联合 PD-1 抑制剂特瑞普利单抗一线治疗晚期非小细胞肺癌（NSCLC）的 1b/2 期研究结果已于去年 ASCO 年会上公布，初诊 NSCLC 患者中 31% 有治疗应答。   默沙东与 Evaxion 深化疫苗合作 Evaxion Biotech 宣布与默沙东就两种临床前候选疫苗签订期权和许可协议。为此，Evaxion 公司将收到 320 万美元的预付款，预付款金额在 2025 年将达到 1000 万美元，并有资格获得开发、监管和销售里程碑付款，每种产品的潜在价值高达 5.92 亿美元，以及净销售额的特许权使用费。 此次协议扩大了两家公司目前的合作范围，Evaxion 公司已授予默沙东临床前候选疫苗 EVX-B2 和 EVX-B3 的独家选择权。其中，EVX-B2 是一种针对淋病的蛋白疗法，EVX-B3 靶向未公开的传染源。   MITEM PHARMA 获得诺华血液学产品全球权利 MITEM PHARMA 宣布，在 TECHLIFE CAPITAL 和 MACSF 的支持下，从诺华获得了血液学产品 Desferal（去铁胺）的全球权利。Desferal 是一种可注射药物，用于治疗慢性铁负荷过重，例如在治疗β地中海贫血和镰状细胞贫血所需的输血后可能发生铁超负荷。该产品已被列入世卫组织基本药物清单。 多家中国公司合作开发新疗法   君实生物子公司与吉盛澳玛达成超 15 亿元合作 君实生物公告表示，其控股子公司君拓生物与吉盛澳玛就后者 IAMA-001 鼻喷剂型项目签署许可及合作协议。根据协议，君拓生物将向吉盛澳玛支付 4000 万元首付款，研发里程碑付款不超过 12.9 亿元，销售里程碑付款不超过 2.5 亿元，总金额达 15.8 亿元。 君拓生物将获得在大中华区研发、生产和商业化 IAMA-001 小核酸免疫调节剂鼻用喷雾剂型药物的独占许可权利，并与君拓生物在大中华区外合作开发 IAMA-001 鼻喷剂型项目。   信念医药与拜耳旗下基因疗法公司达成合作 信念医药宣布与拜耳全资独立运营的基因疗法子公司 Asklepios BioPharmaceutical 达成战略合作，共同探索创新基因疗法潜力。双方将深入研究和探索通过肝脏靶向治疗途径实现创新基因治疗方案的疾病领域。 信念医药专注前沿基因治疗，研发管线覆盖血友病、杜氏肌营养不良症、帕金森病、骨关节炎等领域，其中针对成年血友病 B 的基因疗法已在中国申报上市。AskBio 公司同样专注开发基因治疗药物，其管线覆盖神经肌肉、中枢神经系统、心血管和代谢等领域，其中多个已进入临床前和临床试验阶段。   瑞博生物与 PHEIRON 就 RNA 药物开发达成合作 瑞博生物及其子公司 Ribocure 宣布与 PHEIRON 公司达成战略合作伙伴关系，前者将借助后者先进的 AI 平台加速 RNA 药物的研发。通过整合 PHEIRON 公司 AI 产生的大规模人类多组学遗传数据，瑞博生物在心血管代谢疾病领域的开发能力有望得到增强。 PHEIRON 公司的 AI 平台 PheironGPS 系统性地整合了大规模的人类多组学遗传数据，以精准确定其生物学机制，同时对药物靶点和患者群体的关系提供了清晰见解。 其它授权合作   大冢制药超 11 亿美元收购 Jnana 大冢制药（Otsuka）宣布已完成对 Jnana Therapeutics 的收购，后者已成为大冢美国公司（OAI）的直接子公司。根据协议，大冢制药向 Jnana 公司股东支付了 8 亿美元，以收购该公司所有流通股的对价。此外，大冢制药可能会根据未来开发产品的进展，向 Jnana 公司股东支付至多 3.25 亿美元的开发和监管里程碑付款。 Jnana 公司专注于开发治疗自身免疫性疾病和罕见病的 first-in-class 化合物。其中，主要管线是一种调节肾脏苯丙氨酸重吸收的蛋白质的口服小分子抑制剂 JNT-517，该产品正在开展治疗苯丙酮尿症（PKU）患者的 1b/2 期研究。该公司还在开发针对高度验证靶标的小分子药物，例如干扰素调节因子 3（IRF3），它是产生干扰素的主要转录因子。   Context 超 1.3 亿美元引进 T 细胞结合抗体 Context 公司与 BioAtla 公司宣布签订协议，从 BioAtla 公司获得开发、制造和商业化 T 细胞结合抗体 BA3362 的独家全球许可权益，并将承担和资助所有开发和商业化活动。根据协议，BioAtla 公司将获得高达 1.335 亿美元的总付款，以及销售净额的分级特许权使用费。 BA3362 是一种条件性激活生物制剂（CAB）T 细胞接合剂，旨在优先在肿瘤微环境中发挥活性。它同时靶向 Nectin-4 和 CD3，其中 Nectin-4 在多种癌症中高度且频繁地过表达，是经过 ADC 临床验证的一个抗肿瘤靶点，CD3 是 T 淋巴细胞表面的一类抗原。   灵北制药与 Iambic 达成合作 灵北制药（Lundbeck）与 Iambic Therapeutics 宣布达成战略研究合作，以利用 Iambic 公司人工智能驱动的药物发现平台，加速神经系统性疾病的研究和治疗创新。该协议包括预付款、里程碑付款和特许权使用费。 Iambic 公司的技术平台包括 NeuralPLexer 蛋白配体结构预测技术，它将加速产生新的候选药物，使其成功到达患者的可能性更高。该公司还能在计算机上设计分子，然后在实验室进行测试，这种速度有可能实现传统药物发现方法无法实现的神经学目标。 封面来源：站酷海洛 Plus 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。 编辑：馨药 PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn 多样化功能、可溯源数据…… Insight 数据库网页版等你体验 点击阅读原文，立刻解锁！